{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:27:12Z","timestamp":1777613232215,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>\nAbstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose\n<\/jats:title>\n                <jats:p>Scalp cooling can prevent chemotherapy-induced alopecia (CIA). Previously, the post-infusion cooling time (PICT) could be successfully reduced in docetaxel-treated patients from 90 to 45 and 20\u00a0min. Therefore, it seems plausible that the PICT can be shortened for paclitaxel-treated patients as well.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients treated with weekly paclitaxel were included in this multi-centre trial and randomly assigned to a PICT of 45 or 20\u00a0min. The results were compared to a standard PICT of 90\u00a0min, derived from prospective collected data from the Dutch Scalp Cooling Registry. The primary endpoint was the percentage of patients who decide to not wear a wig or head covering. Secondary endpoints were the degree of CIA assessed with the Dean scale for assessment of hair loss; alopecia graded according to NCI CTC toxicity version 4.03 (CTCAE4.03); tolerance of scalp cooling and perceived distress of CIA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ninety-one patients were enrolled in this study; 74 patients were evaluable for hair loss. Hair preservation was successful in 27 patients (75%) with a PICT of 45\u00a0min and in 31 patients (82%) with a PICT of 20\u00a0min. There was no difference in success rate with the standard PICT of 90\u00a0min (85%, <jats:italic>p<\/jats:italic>\u2009=\u20090.29). Similar success rates were seen when using the Dean scale and CTCAE assessment, with no differences between groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.12 and <jats:italic>p<\/jats:italic>\u2009=\u20090.38).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A 20\u00a0min PICT is as effective as 45 and 90\u00a0min to prevent weekly paclitaxel-induced alopecia and should be the new standard of care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial register\n<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT03266185.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-07090-7","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T22:07:41Z","timestamp":1651529261000},"page":"6641-6648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia \u2014 a randomized controlled trial"],"prefix":"10.1007","volume":"30","author":[{"given":"Rieneke T.","family":"Lugtenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina J. G.","family":"van den Hurk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolien H.","family":"Smorenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Houtsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret A. G. den Hollander-van","family":"Deursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad A.","family":"Kaptein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"issue":"2","key":"7090_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdt476","volume":"25","author":"J Cho","year":"2014","unstructured":"Cho J, Choi EK, Kim IR, Im YH, Park YH, Lee S et al (2014) Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol 25(2):346\u2013351","journal-title":"Ann Oncol"},{"issue":"1","key":"7090_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/0284186X.2013.794955","volume":"53","author":"CJ van den Hurk","year":"2014","unstructured":"van den Hurk CJ, van den Akker-van Marle ME, Breed WP, van de Poll-Franse LV, Nortier JW, Coebergh JW (2014) Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. Acta Oncol 53(1):80\u201387","journal-title":"Acta Oncol"},{"issue":"4","key":"7090_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","volume":"51","author":"CJ van den Hurk","year":"2012","unstructured":"van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497\u2013504","journal-title":"Acta Oncol"},{"issue":"6","key":"7090_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jama.2016.21038","volume":"317","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A et al (2017) Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 317(6):606\u2013614","journal-title":"JAMA"},{"issue":"1","key":"7090_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","volume":"18","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Voigt J (2018) Scalp Hypothermia for preventing alopecia during chemotherapy. a systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer 18(1):19\u201328","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"7090_CR6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.2016.20939","volume":"317","author":"J Nangia","year":"2017","unstructured":"Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S et al (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 317(6):596\u2013605","journal-title":"JAMA"},{"issue":"6","key":"7090_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3109\/00365518509155250","volume":"45","author":"J Bulow","year":"1985","unstructured":"Bulow J, Friberg L, Gaardsting O, Hansen M (1985) Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. Scand J Clin Lab Invest 45(6):505\u2013508","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"7090_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-011-1453-y","volume":"128","author":"J Lemieux","year":"2011","unstructured":"Lemieux J, Desbiens C, Hogue JC (2011) Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up. Breast Cancer Res Treat 128(2):563\u2013566","journal-title":"Breast Cancer Res Treat"},{"key":"7090_CR9","first-page":"A2134","volume":"154","author":"MA van de Sande","year":"2010","unstructured":"van de Sande MA, van den Hurk CJ, Breed WP, Nortier JW (2010) Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur. Ned Tijdschr Geneeskd 154:A2134","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"7090_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-014-3231-0","volume":"149","author":"J Lemieux","year":"2015","unstructured":"Lemieux J, Provencher L, Perron L, Brisson J, Amireault C, Blanchette C et al (2015) No effect of scalp cooling on survival among women with breast cancer. Breast Cancer Res Treat 149(1):263\u2013268","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7090_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10549-017-4185-9","volume":"163","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Melin SA, Voigt J (2017) Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 163(2):199\u2013205","journal-title":"Breast Cancer Res Treat"},{"key":"7090_CR12","doi-asserted-by":"crossref","unstructured":"Komen MM, Breed WP, Smorenburg CH, van der Ploeg T, Goey SH, van der Hoeven JJ et al (2016) Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 24(6):2735\u20132741","DOI":"10.1007\/s00520-016-3084-7"},{"issue":"4","key":"7090_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4103\/apjon.apjon_19_19","volume":"6","author":"C van den Hurk","year":"2019","unstructured":"van den Hurk C, Keizer-Heldens P, Raats I, Hoeijmakers K, Mols F (2019) Improving information provision on chemotherapy-induced alopecia and scalp cooling: a comprehensive approach including a website and web-based decision tool. Asia Pac J Oncol Nurs 6(4):336\u2013342","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"7","key":"7090_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1634\/theoncologist.2012-0332","volume":"18","author":"MM Komen","year":"2013","unstructured":"Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18(7):885\u2013891","journal-title":"Oncologist"},{"key":"7090_CR15","doi-asserted-by":"crossref","unstructured":"van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20(12):3255\u20133260","DOI":"10.1007\/s00520-012-1465-0"},{"issue":"2","key":"7090_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00280-015-2893-6","volume":"77","author":"M Joerger","year":"2016","unstructured":"Joerger M (2016) Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol 77(2):221\u2013233","journal-title":"Cancer Chemother Pharmacol"},{"issue":"26","key":"7090_CR17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1056\/NEJM197912273012605","volume":"301","author":"JC Dean","year":"1979","unstructured":"Dean JC, Salmon SE, Griffith KS (1979) Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med 301(26):1427\u20131429","journal-title":"N Engl J Med"},{"issue":"2","key":"7090_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-020-05968-w","volume":"185","author":"C Villarreal-Garza","year":"2021","unstructured":"Villarreal-Garza C, Mesa-Chavez F, Garza-Ledezma MRA, Pe\u00f1a-Curiel O, Martinez-Cannon BA, Canavati-Marcos M et al (2021) Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention. Breast Cancer Res Treat 185(2):453\u2013458","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7090_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-019-05169-0","volume":"175","author":"DH Marks","year":"2019","unstructured":"Marks DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, Isakoff SJ, Lacouture ME et al (2019) The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. Breast Cancer Res Treat 175(2):267\u2013276","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"7090_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pon.1615","volume":"19","author":"CJ van den Hurk","year":"2010","unstructured":"van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19(7):701\u2013709","journal-title":"Psychooncology"},{"issue":"4","key":"7090_CR21","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/curroncol28040224","volume":"28","author":"D Di Giacomo","year":"2021","unstructured":"Di Giacomo D, Guerra F, Cannita K, Di Profio A, Ranieri J (2021) Digital innovation in oncological primary treatment for well-being of patients: psychological caring as prompt for enhancing quality of life. Curr Oncol 28(4):2452\u20132465","journal-title":"Curr Oncol"},{"key":"7090_CR22","doi-asserted-by":"crossref","unstructured":"Versluis A, van Alphen K, Dercksen W, de Haas H, van den Hurk C, Kaptein AA. \"Dear hair loss\"-illness perceptions of female patients with chemotherapy-induced alopecia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2022.","DOI":"10.1007\/s00520-021-06748-y"},{"issue":"3","key":"7090_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","volume":"24","author":"D Kang","year":"2019","unstructured":"Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS et al (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 24(3):414\u2013420","journal-title":"Oncologist"},{"issue":"3","key":"7090_CR24","doi-asserted-by":"publisher","first-page":"e13395","DOI":"10.1111\/ecc.13395","volume":"30","author":"J Chan","year":"2021","unstructured":"Chan J, Adderley H, Alameddine M, Armstrong A, Arundell D, Fox R et al (2021) Permanent hair loss associated with taxane chemotherapy use in breast cancer: a retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl) 30(3):e13395","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"7090_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/2347-5625.152404","volume":"2","author":"M Peerbooms","year":"2015","unstructured":"Peerbooms M, van den Hurk CJ, Breed WP (2015) Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals. Asia Pac J Oncol Nurs 2(1):35\u201341","journal-title":"Asia Pac J Oncol Nurs"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07090-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07090-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07090-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T05:08:03Z","timestamp":1655788083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07090-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7090"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07090-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the protocol, the ethical principles laid down in the Declaration of Helsinki, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice (ICH GCP), guidelines and applicable regulatory requirements. The protocol, ICF, any other materials provided to the patients, and further requested information were submitted to the IEC\/IRB and the competent authority. The regulatory application or submission for regulatory approval was made by the sponsor or designee as required by national law. The competent authority and the IEC\/IRB were notified of the end of the study in accordance with local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}